B
BVF Partners L.P.
+ HoldingXFOR
+11.78%
3M Return
$4.040
-0.181 (-4.49%)收盤時
Loading chart…
- High
- 4.230
- Open
- 4.220
- VWAP
- 4.09
- Vol
- 356.38K
- Mkt Cap
- 112.54M
- Low
- 4.000
- Amount
- 1.46M
- EV/EBITDA, TTM
- 0.00
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
估值指標
The current forward P/E ratio for X4 Pharmaceuticals Inc (XFOR) is -0.52, compared to its 5-year average forward P/E of -1.85.
Whales holding XFOR
事件時間軸
資訊
9.508-06seekingalphaX4 Pharmaceuticals Q2 Earnings Beat Expectations
8.508-06GlobenewswireX4 Pharmaceuticals Strengthens Clinical Operations, Secures EU Approval for XOLREMDI®
5.008-03GlobenewswireX4 Pharmaceuticals Grants Stock Options to New Employees
5.008-03NewsfilterX4 Pharmaceuticals Grants Stock Options to New Employees
6.007-10CNBCWall Street's Latest Ratings Overview
XFOR FAQ — answered by Alphio AI
X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。